2022 World Conference on Lung Cancer (ePosters)-EP14.01-013. First-Line Chemotherapy vs Chemoimmunotherapy in Stage IV Large Cell Neuroendocrine Carcinoma of the Lung, a Retrospective Study

EP14.01-013. First-Line Chemotherapy vs Chemoimmunotherapy in Stage IV Large Cell Neuroendocrine Carcinoma of the Lung, a Retrospective Study

Back to course

Pdf Summary

This study aimed to investigate the efficacy of adding immune checkpoint inhibitors (ICI) to standard chemotherapy (CT) in the treatment of stage IV large cell neuroendocrine carcinoma of the lung (LCNEC). It is the first study to assess the impact of first-line ICI on the treatment of this rare type of lung cancer.<br /><br />The results showed that the addition of ICI to standard CT demonstrated a positive effect on overall survival (OS), with a trend in progression-free survival (PFS) and objective response rate (ORR). There were almost no severe treatment-related adverse events, except for one case of severe pneumonitis in the patients treated with CT plus ICI.<br /><br />The study had some limitations, including its retrospective nature and small sample size. However, the inclusion of all consecutive patients helped to limit selection bias. Therefore, larger and prospective studies are warranted to further investigate the efficacy of adding ICI to standard CT in the treatment of stage IV LCNEC.<br /><br />The study analyzed the demographics and clinical characteristics of patients with stage IV LCNEC stratified by treatment options (CT only vs CT plus ICI). Patients treated with CT plus ICI showed a trend of higher ORR and disease control rate (DCR), although the increase was not statistically significant.<br /><br />Univariate Cox regression analyses were performed to predict overall survival, and patients treated with CT plus ICI showed a significantly improved OS and a trend of better PFS compared to those treated with CT only.<br /><br />The study included all patients diagnosed with stage IV LCNEC from the Moffitt Cancer Center database who received systemic therapy between June 2016 and June 2021. The two arms of the study included patients who received either first-line CT and ICI or CT only. The analysis included OS, PFS, ORR, and toxicities.<br /><br />In conclusion, this retrospective study suggests that adding ICI to standard CT may have a positive impact on the treatment of stage IV LCNEC. However, further research with larger and prospective studies is needed to confirm these findings.

Asset Subtitle

Lingbin Meng

Meta Tag

Speaker Lingbin Meng

Topic Small Cell Lung Cancer and Neuro-endocrine Tumours - Informing ES-SCLC

Keywords

immune checkpoint inhibitors

chemotherapy

stage IV large cell neuroendocrine carcinoma

lung cancer

overall survival

progression-free survival

objective response rate

treatment-related adverse events

retrospective study

clinical characteristics